Vogt G, le Grand R, Vaslin B, Boussin F, Auboyer M H, Rivière Y, Putkonen P, Sonigo P, Kieny M P, Girard M
Laboratoire de Neuropathologie expérimentale et Neurovirologie, CRSSA, DSV, DPTE, CEA, Fontenay Aux Roses, France.
Vaccine. 1995 Feb;13(2):202-8. doi: 10.1016/0264-410x(95)93137-x.
In an attempt to analyse the role of anti-envelope immunity in the protection of rhesus monkeys against an HIV-2 intravenous challenge, rhesus macaques were immunized twice with recombinant HIV-2 ROD vaccinia viruses (10(8) p.f.u. each) at days 0 and 30, followed by booster injections of purified HIV-2 proteins at months 8, 9, 15 and 27. One group of five macaques was immunized with the Gag, Pol, Vif and Nef antigens, whereas a second group received the same antigens with the addition of HIV-2 Env protein. Eight months after the last boost, the animals were challenged by intravenous injection of 100 AID50 of a monkey PBMC-grown stock of HIV-2 SBL. None of the animals was protected in spite of high humoral immune responses on day of challenge as determined by ELISA and Western Blot assays.
为了分析抗包膜免疫在保护恒河猴抵抗HIV-2静脉内攻击中的作用,在第0天和第30天用重组HIV-2 ROD痘苗病毒(每次10⁸ 蚀斑形成单位)对恒河猴进行两次免疫,随后在第8、9、15和27个月用纯化的HIV-2蛋白进行加强注射。一组五只猕猴用Gag、Pol、Vif和Nef抗原进行免疫,而另一组在相同抗原的基础上添加了HIV-2 Env蛋白。在最后一次加强注射八个月后,通过静脉注射100个艾滋病相关感染剂量50(AID50)的猴外周血单个核细胞(PBMC)培养的HIV-2 SBL毒株对动物进行攻击。尽管通过ELISA和Western Blot检测发现在攻击当天有高体液免疫反应,但没有一只动物得到保护。